CA2316052A1 - Sustained release formulations of water soluble peptides - Google Patents

Sustained release formulations of water soluble peptides Download PDF

Info

Publication number
CA2316052A1
CA2316052A1 CA002316052A CA2316052A CA2316052A1 CA 2316052 A1 CA2316052 A1 CA 2316052A1 CA 002316052 A CA002316052 A CA 002316052A CA 2316052 A CA2316052 A CA 2316052A CA 2316052 A1 CA2316052 A1 CA 2316052A1
Authority
CA
Canada
Prior art keywords
sustained release
water soluble
release formulations
soluble peptides
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002316052A
Other languages
French (fr)
Other versions
CA2316052C (en
Inventor
David Bodmer
Jones W. Fong
Thomas Kissel
Hawkins V. Maulding
Oskar Nagele
Jane E. Pearson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002535463A priority Critical patent/CA2535463A1/en
Priority claimed from CA002020477A external-priority patent/CA2020477C/en
Publication of CA2316052A1 publication Critical patent/CA2316052A1/en
Application granted granted Critical
Publication of CA2316052C publication Critical patent/CA2316052C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Abstract

A sustained release formulation of a peptide drug compound, preferably a somatostatin like octreotide, e.g. as a pamoate salt. The drug compound is present in a polymeric carrier, preferably a polylactide-co-glycolide, especially a poly(lactide-co-glycolide)glucose. The formulation is preferably a depot formulation in the form of a monolithic microparticle.
CA002316052A 1989-07-07 1990-07-05 Sustained release formulations of water soluble peptides Expired - Lifetime CA2316052C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002535463A CA2535463A1 (en) 1989-07-07 1990-07-05 Octreotide-pamoate and its use in sustained release formulations of water soluble peptides

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37702389A 1989-07-07 1989-07-07
US377,023 1989-07-07
US41134789A 1989-09-22 1989-09-22
US411,347 1989-09-22
CA002020477A CA2020477C (en) 1989-07-07 1990-07-05 Sustained release formulations of water soluble peptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002020477A Division CA2020477C (en) 1989-07-07 1990-07-05 Sustained release formulations of water soluble peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002535463A Division CA2535463A1 (en) 1989-07-07 1990-07-05 Octreotide-pamoate and its use in sustained release formulations of water soluble peptides

Publications (2)

Publication Number Publication Date
CA2316052A1 true CA2316052A1 (en) 1991-01-08
CA2316052C CA2316052C (en) 2008-09-02

Family

ID=27168773

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002316052A Expired - Lifetime CA2316052C (en) 1989-07-07 1990-07-05 Sustained release formulations of water soluble peptides

Country Status (1)

Country Link
CA (1) CA2316052C (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008142153A1 (en) * 2007-05-24 2008-11-27 Novartis Ag An extended-release composition comprising a somatostatin derivative in microparticles
US8999390B2 (en) 2008-01-30 2015-04-07 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
EP3242318A1 (en) * 2003-12-19 2017-11-08 The University of North Carolina at Chapel Hill Monodisperse micro-structure or nano-structure product
CN111514118A (en) * 2020-05-06 2020-08-11 南京林业大学 Preparation method of glucose-modified polylactic acid stereocomplex drug-loaded microspheres and product

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3242318A1 (en) * 2003-12-19 2017-11-08 The University of North Carolina at Chapel Hill Monodisperse micro-structure or nano-structure product
US10842748B2 (en) 2003-12-19 2020-11-24 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro- or nano-structures using soft or imprint lithography
US11642313B2 (en) 2003-12-19 2023-05-09 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro- or nano-structures using soft or imprint lithography
WO2008142153A1 (en) * 2007-05-24 2008-11-27 Novartis Ag An extended-release composition comprising a somatostatin derivative in microparticles
US9351923B2 (en) 2007-05-24 2016-05-31 Novartis Ag Extended-release composition comprising a somatostatin derivative in microparticles
EP3666263A1 (en) * 2007-05-24 2020-06-17 Recordati AG An extended-release composition comprising a somatostatin derivative in microparticles
US8999390B2 (en) 2008-01-30 2015-04-07 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
CN111514118A (en) * 2020-05-06 2020-08-11 南京林业大学 Preparation method of glucose-modified polylactic acid stereocomplex drug-loaded microspheres and product

Also Published As

Publication number Publication date
CA2316052C (en) 2008-09-02

Similar Documents

Publication Publication Date Title
MY106722A (en) Sustained release formulations of water soluble peptides.
FI870155A0 (en) Process for the preparation of solid drug preparations containing xanthan gum
CA2075878A1 (en) Cyclic peptides and use thereof
US5044091B1 (en) Method of preparing a freeze-dried formulation of a drug
CA2207078A1 (en) Insulin derivatives with increased zinc binding
WO1995013297A3 (en) Improved immunogenic compositions against human gastrin 17
AU3125389A (en) Intravaginal delivery of biologically active polypeptides
PH30995A (en) Sustained release formulations of water soluble peptides.
UA35569C2 (en) Composition for sustained release of pharmaceutically active peptide and method for its manufacture, method for preparing suspension for parenteral administration
CA2128199A1 (en) Stable Solid Pharmaceutical Compositions Containing Enalapril Maleate
WO1998021237A3 (en) Peptide compounds useful for modulating FGF receptor activity
HK1029124A1 (en) Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them.
RU94005001A (en) PEPTIDE BASED LYOPHYLIZATE
EP0211601A3 (en) Stabilization of growth promoting hormones
CA2316052A1 (en) Sustained release formulations of water soluble peptides
CA2356959A1 (en) Water-insoluble drug delivery system
EP0369474A3 (en) Pharmaceutical composition for the treatment of cerebral edema
WO1988003150A3 (en) N,n'-bis-amino acid-l-cystine-peptide-containing amino acid preparations for oral and parenteral administration
FI991120A (en) Sustained-release compositions of water-soluble peptides
ZA9710254B (en) LH-RH peptide analogues, their uses and pharmaceutical composition containing them.
ES2049617A1 (en) Biodegradable microparticles or implant containing insoluble peptide salts
CA2021923A1 (en) Pharmaceutical composition containing hydantoin derivative
RU96111534A (en) FOOD BIOLOGICALLY ACTIVE ADDITION OF TINROSTIM-S
CS275014B2 (en) Peptides with accumulated pair of basic amino acids
CA2315241A1 (en) Protein rim2

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry